Pharmacological treatments for drug misuse and dependence

Bibliography

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. Washington, DC: 2013
   Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010;35:217-38
   PubMed Web of Science ®Google Scholar
• Davenport Hines RPT. The pursuit of oblivion: a global history of narcotics 1500-2000. Weidenfeld, Great Britain; 2001
   Google Scholar
• Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. Springer-Verlag, New York; 1991
   Google Scholar
• Fareed A, Vayalapalli S, Stout S, et al. Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis 2010;30(1):27-38
   Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Casarella J, et al. Heroin anticraving medications: a systematic review. Am J Drug Alcohol Abuse 2010;36:332-41
   PubMed Web of Science ®Google Scholar
• Lin S-K. Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature. Br J Clin Pharmacol 2013;77(2):242-52
   Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Methadone and Buprenorphine for the management of opioid dependence. NICE technology appraisal guidance 114, London; 2007
   Google Scholar
• Department of Health (England) and the devolved administrations. Drug misuse and dependence: UK guidelines on clinical management. Department of Health (England) the Scottish Government, Welsh Assembly Government and Northern Ireland Executive; London: 2007
   Google Scholar
• Cornish R, Macleod J, Strang J, et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General practice. Research database. BMJ 2010;34:c5475
   Google Scholar
• Fugelstad A, Stenbacka M, Leifman A, et al. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction 2007;102:406-12
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15
   PubMed Web of Science ®Google Scholar
• Davoli M, Bargagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction 2007;102:1954
   PubMed Web of Science ®Google Scholar
• Harding-Pink D. Methadone: one person’s maintenance dose is another’s poison. Lancet 1993;341:665-6
   PubMed Web of Science ®Google Scholar
• Zador D, et al. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000;95:77-84
   PubMed Web of Science ®Google Scholar
• Neale J. Methadone, methadone treatment and non-fatal overdose. Drug Alcohol Depend 2000;58:117-24
   PubMed Web of Science ®Google Scholar
• Strang J, Powis B, Best D, et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction 1999;94:199-204
   PubMed Web of Science ®Google Scholar
• Strang J, Manning V, Mayet S, et al. Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. Addiction 2008;103:1648-57
   PubMed Web of Science ®Google Scholar
• Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-4
   PubMed Web of Science ®Google Scholar
• Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 2003;105:499-506
   PubMed Web of Science ®Google Scholar
• Martell BA, Arnsten JH, Ray B, Gourevitch MN. The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med 2003;139:154-5; 22
   PubMed Web of Science ®Google Scholar
• Risk of QT interval prolongation with methadone. Curr Probl Pharmacovigilance 2006;31:6
   Google Scholar
• Taylor D, Paton C, Kapur S. editors. The Maudsley prescribing guidelines in psychiatry. 11th edition. Wiley-Blackwell, UK; 2012. 978-1-118-32325-0
   Google Scholar
• Alho H Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine–naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007;88:75-8
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Johnson RE. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006;83(Suppl 1):S40-7
   PubMedGoogle Scholar
• Bond AJ, Reed KD, Beavan P, Strang J. After the randomised injectable opiate treatment trial: post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication. Drug Alcohol Rev 2012;31:492-8
   PubMed Web of Science ®Google Scholar
• EMEA (European Agency for the Evaluation of Medicinal Products). EMEA public statement on the recommendation to suspend the marketing authorization for Orlaam (levacetylmethadol) in the European Union. 2001. (19 April); EMEA/8776/01 Available from: http:\\www.emea.eu.int/
   Google Scholar
• Broomhead A, West R, Eglinton L, et al. Comparative single dose pharmacokinetics of sustained release and modified release morphine sulphate capsules under fed and fasting conditions. Clin Drug Investig 1997;13:162-70
   Web of Science ®Google Scholar
• Aeschbach Jachmann C, Jagsch R, Winklbaur B, et al. Office-based treatment in opioid dependence: a critical survey of prescription practices for opioid maintenance medications and concomitant benzodiazepines in Vienna, Austria. Eur Addict Res 2008;14:206-12
   PubMed Web of Science ®Google Scholar
• Strang J, Ruben S, Farrell M, et al. The history of prescribing heroin and other injectable drugs as addiction treatment in the UK. In: Strang J, Gossop M, editors. Heroin addiction and The ‘British System’. Volume 2 Treatment & Policy Responses Routledge, London; 2005. p. 1-16
   Google Scholar
• Strang J, Metrebian N, Lintzeris N, et al. Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial. Lancet 2010;375:1885-95
   PubMed Web of Science ®Google Scholar
• Department of Health. Available from: http://www.dh.gov.uk/health/2012/01/iotservice-provider-briefing [Accessed January 2012]
   Google Scholar
• NICE Clinical guidelines, CG52 - Issued: July 2007
   Google Scholar
• Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001;68:1
   Google Scholar
• Strang J, Bearn J, Gossop M. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict 1999;8(4):337-48
   PubMed Web of Science ®Google Scholar
• Gowing L, Farrell M, Ali R, White JM. Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2009(2):CD002024
   PubMed Web of Science ®Google Scholar
• Naltrexone for the management of opioid dependence. NICE technology appraisal 115; 2007
   Google Scholar
• O’Brien C. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005;162:1423-31
   PubMed Web of Science ®Google Scholar
• Vickers AP, Jolly A. Naltrexone and problems in pain management. BMJ 2006;332:132-3
   PubMedGoogle Scholar
• Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003;8(2):211-17
   PubMed Web of Science ®Google Scholar
• Lingford-Hughes AR, Welch S, Peters L, Nutt DJ. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012;26:899-952
   PubMed Web of Science ®Google Scholar
• Johnson BA, Johnson BAAit-Daoud N, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013;70(12):1338-46
   PubMed Web of Science ®Google Scholar
• Winstock AR, Ford C, Witton J. Assessment and management of cannabis use disorders in primary care. BMJ 2010;340:c1571
   PubMed Web of Science ®Google Scholar
• British medical association drugs of dependence: the role of medical professionals. BMA Board of Science, BMA Science and Education department and the Board of Science; 2013
   Google Scholar
• Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of d9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010;35:1879-85
   PubMed Web of Science ®Google Scholar
• Cannabidiol: a novel treatment for cannabis dependence? University College London. Available from: http://gtr.rcuk.ac.uk/project/0264FAF2-1CE1-4894-BE33-C53A27E49217
   Google Scholar
• Holmes D. Prescription drug addiction: the treatment challenge. Lancet 2012;379:17-18
   PubMed Web of Science ®Google Scholar
• Public Health England Public Health England. Commissioning treatment for dependence on prescription and over-the-counter medicines: a guide for NHS and local authority commissioners. Available from: http://www.nta.nhs.uk/uploads/pheatmcommissioningguide.pdf [Last accessed 4 July 2013]
   Google Scholar
• Dhalla I, Persaud N, Juurlink D. Facing up to the prescription opioid crisis. BMJ 2011;343:d5142
   PubMedGoogle Scholar
• RCGP Substance Misuse and Associated Health: prescription and over-the counter medicines misuse and dependence. Available from: http://www.rcgp.org.uk/Addiction-to-Medicines-Factsheet
   Google Scholar
• Bell J, Reed K, Gross S, Witton J. editors. The management of pain in people with a past or current history of addiction. Action on Addiction, Salisbury, UK; 2013
   Google Scholar
• Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010;304(14):1576-83
   PubMed Web of Science ®Google Scholar
• Comer SD, Collins ED, Kleber HD, et al. Depot Naltrexone: long lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl) 2002;159:351-60
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011;377:1506-13
   PubMed Web of Science ®Google Scholar
• Kosten T, Domingo C, Orson F, Kinsey B. Vaccines against stimulants: cocaine and MA. Br J Clin Pharmacol 2014;77(2):368-74
   PubMed Web of Science ®Google Scholar
• Vocci FJ, Chiang CN. Vaccines against nicotine: how effective are they likely to be in preventing smoking? CNS Drugs 2001;15(7):505-14
   PubMed Web of Science ®Google Scholar
• Schlosburg J, Vendruscolo L, Bremer P, et al. Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci USA 2013;110(22):9036-41
   PubMed Web of Science ®Google Scholar